Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

626
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
626
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.8K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

468
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
468
Long-term Depression01:05

Long-term Depression

33.3K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
33.3K
Long-term Depression01:03

Long-term Depression

3.4K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
3.4K
Freezing Point Depression and Boiling Point Elevation03:12

Freezing Point Depression and Boiling Point Elevation

40.1K
Boiling Point Elevation
The boiling point of a liquid is the temperature at which its vapor pressure is equal to ambient atmospheric pressure. Since the vapor pressure of a solution is lowered due to the presence of nonvolatile solutes, it stands to reason that the solution’s boiling point will subsequently be increased. Vapor pressure increases with temperature, and so a solution will require a higher temperature than will pure solvent to achieve any given vapor pressure, including one...
40.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Electroconvulsive Therapy and the Longitudinal Modulation of Sleep Architecture.

The journal of ECT·2026
Same author

Investigating the impact of electroconvulsive therapy on brain networks and sleep: an observational study protocol.

BMJ open·2025
Same author

Propofol enhancement of slow wave sleep to target the nexus of geriatric depression and cognitive dysfunction: protocol for a phase I open label trial.

BMJ open·2024
Same author

Ketamine for postoperative avoidance of depressive symptoms: the K-PASS feasibility randomised trial.

BJA open·2024
Same author

Education Innovations in the Department of Psychiatry at Washington University.

Missouri medicine·2023
Same author

Movements and central positive complexes during an ECT-induced seizure: A video-EEG case.

Epileptic disorders : international epilepsy journal with videotape·2023

Related Experiment Video

Updated: Feb 2, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.6K

NMDA Antagonists for Treatment-Resistant Depression.

Nuri B Farber1

  • 1Residency Training, Department of Psychiatry, Washington University in St. Louis, St. Louis, MO, USA. farbern@wustl.edu.

Handbook of Experimental Pharmacology
|November 28, 2018
PubMed
Summary

N-methyl-D-aspartate (NMDA) antagonists like ketamine show promise for treatment-resistant depression. While effective, further research is needed to optimize dosing and manage side effects for routine clinical use.

Keywords:
CERC-301KetamineMajor depressive disorderMemantineNMDA antagonistsNitrous oxideRapastinelTreatment-resistant depression

More Related Videos

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.6K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.2K

Related Experiment Videos

Last Updated: Feb 2, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
08:20

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder

Published on: August 11, 2015

14.6K
Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression
04:29

Vagus Nerve Stimulation As an Adjunctive Neurostimulation Tool in Treatment-resistant Depression

Published on: January 7, 2019

29.6K
Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.2K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Major depressive disorder (MDD) affects 15-30% of patients unresponsive to traditional monoaminergic antidepressants.
  • N-methyl-D-aspartate (NMDA) receptor antagonists are emerging as a novel therapeutic strategy for treatment-resistant depression.

Purpose of the Study:

  • To review the current evidence for NMDA antagonists, particularly ketamine, in treating major depressive disorder.
  • To discuss the efficacy, side effect profile, and future research directions for NMDA receptor blockade in depression.

Main Methods:

  • Review of clinical studies on ketamine, nitrous oxide, CERC-301, and rapastinel for depression.
  • Analysis of reported efficacy, duration of response, and psychotomimetic/cognitive side effects.
  • Examination of findings from a pilot study using a 96-h ketamine infusion with clonidine.

Main Results:

  • Ketamine, administered as a brief infusion or multiple doses, provides rapid but temporary relief from depressive symptoms.
  • A 96-h ketamine infusion with clonidine showed sustained response in 40% of subjects at 8 weeks in a pilot study.
  • Nitrous oxide and other investigational agents like CERC-301 and rapastinel also show positive results, with similar side effect profiles.

Conclusions:

  • NMDA receptor blockade offers a promising avenue for treatment-resistant depression, evidenced by ketamine's rapid antidepressant effects.
  • Further research is crucial to establish optimal dosing, administration schedules, and effective mitigation strategies for NMDA antagonist-induced side effects.
  • Overcoming these challenges is essential for the routine clinical application of ketamine and similar NMDA antagonists in managing depression.